ketorolac has been researched along with Anemia, Sickle Cell in 12 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients receiving ketorolac and those receiving placebo were of similar age, weight, gender, number of prior ED visits, number of prior hospital admissions, duration of pain prior to presentation, and initial pain score." | 9.09 | Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. ( Givens, TG; Hardwick, WE; King, WD; Lawley, D; Monroe, KW, 1999) |
| "To determine if a single dose of intramuscular ketorolac given on presentation to the emergency department has a narcotic-sparing effect in adult patients with sickle cell vaso-occlusive crisis pain." | 9.07 | Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. ( Mitchell, TR; Norris, RL; Wright, SW, 1992) |
| "Patients receiving ketorolac and those receiving placebo were of similar age, weight, gender, number of prior ED visits, number of prior hospital admissions, duration of pain prior to presentation, and initial pain score." | 5.09 | Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. ( Givens, TG; Hardwick, WE; King, WD; Lawley, D; Monroe, KW, 1999) |
| "To determine if a single dose of intramuscular ketorolac given on presentation to the emergency department has a narcotic-sparing effect in adult patients with sickle cell vaso-occlusive crisis pain." | 5.07 | Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. ( Mitchell, TR; Norris, RL; Wright, SW, 1992) |
| " The MQS score accounted for variations in the types of analgesic medications, routes of administration, dosing schedules, and opioid dosing requirements." | 1.34 | Quantification of analgesic use in children with sickle cell disease. ( Beyer, JE; Jacob, E; Miaskowski, C; Savedra, M; Styles, L; Treadwell, M, 2007) |
| "The gene for sickle cell disease is carried by 8% of the African-American population in the United States." | 1.28 | Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. ( Pollack, CV; Sanders, DY; Severance, HW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Franceschi, L | 2 |
| Mura, P | 1 |
| Schweiger, V | 1 |
| Vencato, E | 1 |
| Quaglia, FM | 1 |
| Delmonte, L | 1 |
| Evangelista, M | 1 |
| Polati, E | 1 |
| Olivieri, O | 1 |
| Finco, G | 2 |
| Baddam, S | 1 |
| Aban, I | 1 |
| Hilliard, L | 1 |
| Howard, T | 1 |
| Askenazi, D | 1 |
| Lebensburger, JD | 1 |
| Baker, M | 1 |
| Hafner, JW | 1 |
| Jacob, E | 2 |
| Miaskowski, C | 2 |
| Savedra, M | 2 |
| Beyer, JE | 2 |
| Treadwell, M | 2 |
| Styles, L | 2 |
| Vassanelli, A | 1 |
| Zaia, B | 1 |
| Ischia, S | 1 |
| Corrocher, R | 1 |
| Richardson, P | 1 |
| Steingart, R | 1 |
| Simckes, AM | 1 |
| Chen, SS | 1 |
| Osorio, AV | 1 |
| Garola, RE | 1 |
| Woods, GM | 1 |
| Hardwick, WE | 1 |
| Givens, TG | 1 |
| Monroe, KW | 1 |
| King, WD | 1 |
| Lawley, D | 1 |
| Sanders, DY | 1 |
| Severance, HW | 1 |
| Pollack, CV | 1 |
| Wright, SW | 1 |
| Norris, RL | 1 |
| Mitchell, TR | 1 |
| Goodman, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease[NCT02373241] | Phase 2 | 1 participants (Actual) | Interventional | 2015-04-30 | Terminated (stopped due to Estimated GFR was determined not to be a reliable endpoint for this study. We identified significant variabilty in annual eGFR that it became inappropriate to randomize to a medication but use EGFR as the primary endpoint.) | ||
| Acute Kidney Injury in Patients With Sickle Cell Disease[NCT03105271] | 60 participants (Actual) | Observational | 2017-01-01 | Completed | |||
| A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis[NCT00094887] | Phase 2 | 150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Outcome 1a. Document the rate of acceptance (quantitative) and reasons for acceptance/rejection (qualitative) in a randomized trial of trial of losartan for SCD patients with abnormal nocturnal blood pressures.~Outcome 1b. Identify the adherence rate to losartan during a randomized three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure.~Outcome 1c. Determine the adherence rate to study procedures among participants enrolled in a three year trial of losartan for SCD patients (n=40) with abnormal nocturnal blood pressure." (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
As a feasibility trial, the effect of losartan on lowering nocturnal hypertension will be monitored to identify the difference in nocturnal BP improvement between the two treatment arms, and within group standard deviation of BP (NCT02373241)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental Blood Pressure Management | 1 |
We will prospectively evaluate the incidence of hypertension (Clinic BP in pts >5yrs and ABPM in pts >10 yrs) and role of blood and urine biomarkers (pts >5ys) among participants with HbSS or SB0 thalassemia (expected cohort n=200) over 5 yrs. We identified 20 participants (34%) with incident hypertension but randomized one to the study. The study was terminated as the eGFR was determined not to be a reliable endpoint in pediatric sickle cell. (NCT02373241)
Timeframe: 5 yrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Blood Pressure Management | 0 |
| Experimental Blood Pressure Management | 1 |
Length of hospitalization is defined as the length of time from admission to discharge order (NCT00094887)
Timeframe: within 40 days
| Intervention | Days (Median) |
|---|---|
| Inhaled Nitric Oxide | 4.06 |
| Placebo | 3.11 |
(NCT00094887)
Timeframe: within 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 5 |
| Placebo | 7 |
Number of participants who required a blood transfusion before discharge because of acute chest syndrome/pneumonia (NCT00094887)
Timeframe: within 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 8 |
| Placebo | 7 |
"VOC resolution was defined by all of the following conditions:~Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best)~Freedom from parenteral narcotic use,~Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis,~Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment." (NCT00094887)
Timeframe: within 30 days
| Intervention | Hours (Median) |
|---|---|
| Inhaled Nitric Oxide | 61.83 |
| Placebo | 55.16 |
The number of participants readmitted to the hospital for any reason within 30 days after discharge (NCT00094887)
Timeframe: during first 24 hours and during 30 day follow-up
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| during first 24 hours | during 30-day follow-up | |
| Inhaled Nitric Oxide | 0 | 9 |
| Placebo | 0 | 17 |
The total dose (mg) of opioid medications received during the trial (NCT00094887)
Timeframe: within 8 hours and within 40 days
| Intervention | mg (Median) | |
|---|---|---|
| within 8 hours | within 40 days | |
| Inhaled Nitric Oxide | 16.25 | 153.75 |
| Placebo | 17.25 | 211.37 |
2 trials available for ketorolac and Anemia, Sickle Cell
| Article | Year |
|---|---|
Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Blood Vessels; Child; Double-Blind | 1999 |
Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect.
Topics: Acute Disease; Adult; Analgesics; Anemia, Sickle Cell; Double-Blind Method; Emergencies; Female; Hum | 1992 |
10 other studies available for ketorolac and Anemia, Sickle Cell
| Article | Year |
|---|---|
Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
Topics: Administration, Buccal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammator | 2016 |
Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.
Topics: Acute Kidney Injury; Acute Pain; Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Ster | 2017 |
Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.
Topics: Acute Kidney Injury; Acute Pain; Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Ster | 2017 |
Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.
Topics: Acute Kidney Injury; Acute Pain; Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Ster | 2017 |
Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis.
Topics: Acute Kidney Injury; Acute Pain; Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Ster | 2017 |
What is the best pharmacologic treatment for sickle cell disease pain crises?
Topics: Adrenal Cortex Hormones; Adult; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Child; | 2012 |
Management of vaso-occlusive pain in children with sickle cell disease.
Topics: Adolescent; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Infl | 2003 |
A pilot study on the efficacy of ketorolac plus tramadol infusion combined with erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle cell pain.
Topics: Adolescent; Analgesics; Anemia, Sickle Cell; Child; Child, Preschool; Combined Modality Therapy; Cyt | 2004 |
Quantification of analgesic use in children with sickle cell disease.
Topics: Adolescent; Adult; Analgesics; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammatory Agents, No | 2007 |
Meperidine and ketorolac in the treatment of painful sickle cell crisis.
Topics: Analgesics; Anemia, Sickle Cell; Humans; Ketorolac; Meperidine; Pain; Tolmetin | 1993 |
Ketorolac-induced irreversible renal failure in sickle cell disease: a case report.
Topics: Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ketorolac; | 1999 |
Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department.
Topics: Acetaminophen; Adolescent; Adult; Amitriptyline; Analgesics; Anemia, Sickle Cell; Anti-Inflammatory | 1992 |
Use of ketorolac in sickle-cell disease and vaso-occlusive crisis.
Topics: Adult; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ketorolac; Pain | 1991 |